Although adeno-associated viral vectors have been studied for a long time, its importance as a viable gene therapy strategy has been thrusted into the limelight only in the recent years. Due to the admirable characteristics of these vectors, their potential has been thoughtfully utilized in the treatment of several neurodegenerative diseases. This mini-review focuses at recapitulating the therapeutic advances of adeno-associated viral vectors in the treatment of Parkinson’s disease by studying the various animal model experiments and clinical trials conducted since the advent of adeno-associated viral vector - based gene therapy. Additionally, the chronological analysis of the studies in the review makes it easier to understand the challenges and foretell the future prospects in this field of therapeutics.